Drug Profile
EDP 1815
Alternative Names: EDP-1815Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Evelo Biosciences
- Developer Cambridge University Hospitals; Evelo Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Bacteria; Immunotherapies; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Immunomodulators; Microbiome modulators; Toll-like receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atopic dermatitis; COVID 2019 infections; Inflammation; Psoriasis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Atopic-dermatitis in United Kingdom (PO, Capsule)
- 26 Jan 2024 Discontinued - Clinical-Phase-Unknown for Inflammation (In volunteers) in USA (PO)
- 26 Jan 2024 Discontinued - Phase-I for Atopic dermatitis in United Kingdom, United Kingdom (PO)